SUMO1–3 levels are upregulated in NPM-ALK+ T-cell lymphoma cell lines and ALK+ T-cell lymphoma patient tumors, whereas SENP1 levels are significantly downregulated. Here, ALK is linked to T-cell non-Hodgkin lymphoma.